lorlatinib (Lorbrena)
Jump to navigation
Jump to search
Indications
- treatment of ALK-positive non-small cell lung cancer[2][3]
Dosage
Tabs: 25 mg, 100 mg
Pharmacokinetics
- crosses blood brain barrier
Mechanism of action
- binds to & inhibits both anaplastic lymphoma kinase (ALK) & ROS1 kinase
More general terms
References
- ↑ PubChem: 71731823
- ↑ 2.0 2.1 Otto MA Lorlatinib: Another First-Line Option for ALK-Positive NSCLC? Medscape - Sep 23, 2020. https://www.medscape.com/viewarticle/937935
- ↑ 3.0 3.1 Shaw AT, Bauer TM, de Marinis F et al First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020; 383:2018-2029 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33207094 https://www.nejm.org/doi/full/10.1056/NEJMoa2027187